Citi upgraded BioAge Labs (BIOA) to Buy from Neutral with a price target of $10, up from $5. The firm believes the company’s BGE-102 can become a “differentiated” NLRP3 inhibitor in treating obesity.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA: